MedWatch

Topotarget-CEO: Orphan-status eases partner search

Approval of the drug belinostat as an Orphan Drug in the EU will not have an immediate effect, but it can prove highly useful later on, says the CEO of Topotarget. He also explains the reason for the recent disagreement with the biotech company’s US partner.

Foto: PR foto/Topotarget

It has no real impact at the moment, but going forward it could help the company’s efforts to develop belinostat for the European market, says Topotarget CEO Anders Vadsholdt following the announcement that the company’s most promising candidate drug had achieved Orphan Drug-status in the EU.

“For everyone, also potential partners, it is of great value that we’ve been given these opportunities. Because it is not just within PTCL (Peripheral T Cell Lymphoma) that we can gain this status, we can probably gain it for other indications as well. I believe, it will make it easier to attract investors and partners, as it is a validation,” Anders Vadsholdt tells Medwatch.

Læs hele artiklen

Få 14 dages fri adgang.

Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

CHMP anbefaler coronapille fra Pfizer

Pfizer har fået en positiv anbefaling fra CHMP, der anbefaler at tabletbehandlingen Paxlovid godkendes til behandling af covid-19. I Danmark er midlet dog allerede taget i brug.

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier